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Background: It is commonly assumed that there are clear lines of demarcation between 
anxiety and depressive disorders on the one hand and psychosis on the other. Recent 
evidence, however, suggests that this principle may be in need of updating. Methods: 
Depressive and/or anxiety disorders, with no previous history of psychotic disorder, were 
examined for the presence of psychotic symptoms in a representative community sample of 
adolescents and young adults (Early Developmental Stages of Psychopathology study; 
n=3021). Associations and consequences of psychotic symptomatology in the course of these 
disorders were examined in terms of demographic distribution, illness severity, onset of 
service use, and risk factors. Results: Around 27% of those with disorders of anxiety and 
depression displayed one or more psychotic symptoms, vs 14% in those without these 
disorders (OR 2.23, 95% CI 1.89–2.66, P < .001). Presence as compared with nonpresence of 
psychotic symptomatology was associated with younger age (P < .0001), male sex (P < 
.0058), and poorer illness course (P < .0002). In addition, there was greater persistence of 
schizotypal (P < .0001) and negative symptoms (P < .0170), more observable illness behavior 
(P < .0001), greater likelihood of service use (P < .0069), as well as more evidence of familial 
liability for mental illness (P < .0100), exposure to trauma (P < .0150), recent and more 
distant life events (P < .0006–.0244), cannabis use (P < .0009), and any drug use (P < .0008). 
Conclusion: Copresence of psychotic symptomatology in disorders of anxiety and depression 
is common and a functionally and etiologically highly relevant feature, reinforcing the view 
that psychopathology is represented by a network or overlapping and reciprocally impacting 
dimensional liabilities.    
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Introduction   
 
Affective dysregulation and reality distortion are correlated but separable dimensions of 
psychopathology.1 The association is present over the continuum of subclinical and clinical 
expression of psychopathology, although stronger in the clinical range.2 Symptoms and 
syndromes of depression and anxiety3,4 are present in the majority of patients with 
schizophrenia, and these affective symptoms may distinguish distinct subgroups within 
clinical samples of individuals with psychotic illness.5 Although the combination of affective 
disorder with superimposed psychotic disorder is considered rare,6 psychotic symptoms are 
often reported in patients with affective disorders. 7,8 Interestingly, the great majority of help-
seeking individuals meeting ultra–high risk criteria (UHR) for psychotic disorder in fact 
initially presents with anxiety disorder or major depression,9–11 and the same is reported in 
individuals at psychometric risk for psychosis.12 Epidemiological community and general 
population studies have furthermore reported strong associations between the subclinical 
expression of affective and psychotic symptoms.13,14   
 
Thus, affective dysregulation (anxiety and depression) and reality distortion are coexpressed 
across the range of subclinical and clinical expression. In part, this may be considered the 
result of mental states that causally impact on each other, eg, affective dysregulation giving 
rise to psychotic symptoms.15–17 In addition, genetic studies have suggested familial links 
between affective and psychotic disorders18,19 as well as between schizophrenia and a range of 
other mental disorders in the nonpsychotic spectrum,20 suggesting shared liabilities. 
Furthermore, dimensions of affective and psychotic pathology are associated with similar risk 
factors,19,21 although quantitative differences exist in strength of association. There is also 
evidence of shared underlying endophenotypes such as alterations in cognition,19,22 as well as 
social and emotional functioning.6,19 Additional support for a common factor underlying both 
affective and psychotic pathology, or for reciprocal causal influence, comes from longitudinal 
studies showing that subclinical psychotic experiences predict not only later onset of 
psychotic disorders23 but also later affective disorders24, even when the psychotic experiences 
are not considered clinically relevant.25   
 
Evidence suggests that the predictive value of either psychotic or affective symptoms for later 
psychopathology and worse outcome is highest when they co-occur. One study showed that 
copresence of subclinical manic and psychotic experiences predicted the development of 
bipolar disorder more strongly than subclinical manic experiences in isolation.26 Likewise, the 
risk of developing a psychotic disorder was higher for individuals with combined expression 
of subclinical psychotic and affective experiences compared with those with only expression 
of psychotic experiences.27 Furthermore, co-occurrence of subclinical psychotic experiences 
predicted poorer outcome in a community sample of patients with major depressive 
disorder.28   
 
In sum, affective and psychotic phenomena often co-occur, partly on the basis of shared 
vulnerability and partly on the basis of reciprocal causal influence; co-occurrence predicts 
poorer course and outcome. These findings have major conceptual and practical implications 
for diagnosis and treatment. Classificatory principles for mental disorders have been 
dominated by the nomothetic approach in which criteria relating to symptoms and complaints 
in patients are assumed to be indicators of an underlying latent diagnostic construct. This 
approach, however, may not be in agreement with evidence that symptoms in practice form 
part of overlapping and reciprocally impacting dimensional liabilities that give rise to highly 
patient-specific admixtures and trajectories.29 Given the above findings, it may well be that 
interindividual differences in dimensions that cross the boundaries of traditional disorders 
have been neglected to the point that important patterns of admixture impacting severity, 
course, and etiology have been overlooked. A case in point is the group of disorders of 
anxiety/depression that traditionally are not considered as fundamentally related to expression 
of psychosis. Instead, expression of psychosis in these disorders is reserved for the definition 
of rare cases where psychotic symptoms are dominant and clinically severe (as in the case of 
major depression with psychotic features). However, given the above suggestion of 
substantial shared vulnerability, shared expression, and reciprocal impact between affective 
dysregulation and reality distortion, the following questions suggest themselves: (1) how 
frequent is the expression of psychotic experiences in broadly defined disorders of anxiety 
and depression? and (2) does the occurrence of psychotic symptoms matter in terms of 
demography, onset, severity, and etiology?   
 
Methods   
 
Sample   
 
Data from the Early Developmental Stages of Psychopathology (EDSP) study were used. The 
EDSP study collected data on prevalence, incidence, risk factors, comorbidity, and course of 
mental disorders in a representative general population sample of adolescents and young 
adults. Detailed descriptions of the study, sampling methods, instruments, and procedures can 
be found elsewhere.30–32 The study was approved by the standing ethics committee. The 
baseline sample was drawn from population registry offices of Munich and its 29 counties in 
1994. This sample was drawn to mirror the distribution of individuals expected to be 14–24 
years of age at the time of the baseline (T0) interview in 1995. The EDSP study was designed 
as a prospective, longitudinal study consisting of 4 data waves: baseline (T0) and 3 follow-up 
waves at an average of, respectively, 1.6 (T0– T1, SD 0.2), 3.5 (T0–T2, SD 0.3), and 8.4 (T0–
T3, SD 0.7) years after T0. The younger participants (14–17 y) were assessed 4 times and 
subjects aged 18–24 years only 3 times. For the current analyses, data from the waves with all 
participants were used (T0, T2, and T3).   
 
Instruments   
 
Psychopathology. Symptoms, syndromes, and disorders were assessed with the computer-
assisted version of the Munich-Composite International Diagnostic Interview (DIA-X/M-
CIDI),33 an updated and expanded version of the WHO’s CIDI version 1.2 (WHO 1990). The 
DIA-X/M-CIDI is a comprehensive, fully standardized, diagnostic interview, addressing 
symptoms, syndromes, and diagnoses of a wide range of mental disorders in accordance with 
definitions and criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition and International Classification of Diseases, Tenth Edition. The M-CIDI has been 
shown to be both reliable and valid. Interviews were conducted by fully trained and 
experienced psychologists, who were allowed to probe with follow-up questions, which is 
particularly relevant for the assessment of psychotic symptoms because these are sensitive to 
false-positive ratings. The EDSP covers a total observation period of up to 10 years. At T0 
(baseline), the lifetime version of the DIA-X/M-CIDI was used; for subsequent waves, the 
respective DIA-X/M-CIDI interval versions were used. Based on the relevant anxiety disorder 
and depression sections, dichotomous variables were constructed representing whether an 
individual had received (1) or had not received (0) a diagnosis of, respectively, a major 
depressive disorder or any anxiety disorder (includes panic disorder, General Anxiety 
Disorder [GAD], agoraphobia, specific phobias, and social anxiety disorder, posttraumatic 
stress disorder [PTSD], and Obsessive Compulsive Disorder [OCD]). The course of disorders 
of anxiety/depression was measured as the number of times an individual had received any 
diagnosis in these sections at each wave, at T0, T2, and T3 (range 0–3). Thus, a score of 3 
indicates the presence of any anxiety and depressive disorder at all 3 time points. The G-
section of the interview on psychotic symptoms and their clinical relevance were only 
collected at T2 (lifetime version) and T3 (interval version). Presence of positive psychotic 
symptoms was broadly defined as any rating of „present“ on any of the 20 core psychosis 
items, as described previously.34 Based on the CIDI measures described above, a 3-level 
variable was constructed indicating whether an individual had (0) no affective (ie, major 
depressive disorder or any anxiety) disorder and no CIDI psychotic symptoms (the reference 
group), (1) an affective disorder but no CIDI psychotic symptoms, or (2) an affective disorder 
and CIDI psychotic symptoms at either T2 or T3. This variable effectively expressed lifetime 
coexpression of the behavioral liability to psychosis in individuals with major depressive 
disorder or any anxiety disorder and is hereafter referred to as „disorders of 
anxiety/depression.“ Individuals with a diagnosis of psychotic disorder at T2 or T3 (N = 21) 
or bipolar disorder (bipolar I or bipolar II) at any time point (N = 90) were excluded from 
analysis, as otherwise any differences between disorders of anxiety/ depression with and 
without psychotic symptoms would be confounded by psychotic disorder.   
 
Suicidal ideation was addressed with CIDI items rating whether the participant had ever had 
thoughts about suicide, conforming to previous work.35 Item ratings were summed over the 3 
assessments (range of possible values for each: 0–3).   
 
Negative symptoms were coded as present when the interviewer rated as present item X11 (on 
flat emotions) and/or X12 (on inadequate communication), in line with previous analyses in 
this sample.34 Persistence of negative symptoms was calculated by scoring whether any 
negative symptom was present never (0) or at 1 (1), 2 (2), or all (3) time points, as described 
previously.   
 
The Symptom Checklist-90-R (SCL-90-R), a reliable and valid screening instrument for a 
range of symptoms occurring in the last week, was also administered at all time points. The 
SCL-90 subscales on psychoticism and paranoid ideation, which rate a broader psychosis 
phenotype indexing the personality – or schizotypal – dimension of psychosis, were summed 
to create an SCL-schizotypy score at each time point. Persistence of schizotypy expression 
was subsequently calculated by scoring whether an individual was in the highest 10% of SCL-
schizotypy scores never (0) or at 1 (1), 2 (2), or all (3) time points.36 Because this schizotypy 
persistence score was based on the SCL-90-R and not on the CIDI, it could be used to 
compare anxiety/ depression groups with and without CIDI psychotic symptoms.   
 
Clinical Relevance. Help-Seeking Behavior In line with previous analyses reported 
elsewhere,36 help-seeking behavior was defined as general help-seeking behavior, which was 
broadly defined as having visited any mental health institution ever for any mental health 
problem (based on the Q-section of the M-CIDI).   
 
Caseness Based on the X16 M-CIDI item, a variable indicating „caseness“ was constructed, 
reflecting the interviewer’s opinion on clinical evidence of mental illness in the participant, 
scored as not noticeable (0), slightly noticeable (1), clearly noticeable (2), and very ill (3). 
Conforming to previous work,36 a dichotomous variable was made based on this item 
indicating presence of clearly noticeable level of mental disorder (defined as score >1).   
 
Psychiatric Medication Use As part of a module assessing mental health treatments, 
participants were shown a list of different types of medication and were asked to endorse 
those they had been given for any psychopathological or psychosomatic problem. The 
acknowledgment of any psychiatric medication other than antipsychotic medication at T2 and 
T3 was rated and used as a binary variable in the analyses.   
 
Risk Factors. Substance Use Substance use from any drug or nonprescribed medication was 
assessed with the L-section of the M-CIDI, assessed at all 3 time points. Conforming to 
previous work,37 2 variables indexing substance use were defined dichotomously as use of (1) 
any substance and (2) cannabis more than 5 times ever at each time point.   
 
Trauma Self-reported lifetime exposure to trauma was assessed using the N-section of the M-
CIDI on trauma and PTSD comprising 9 groups of specific traumatic events (presented by a 
respondent list) such as „experienced physical threat“, „experienced serious accident“, or 
„being sexually abused as a child.“ Consistent with earlier analyses,38 positive responses to 
any of the events were coded as „self-reported trauma.“   
 
Recent Life Events Recent life events were assessed at T2 with the Munich Interview for the 
Assessment of Life Events and Conditions (Münchner Ereignis Liste); a reliable 3-step 
interview assessing recent life events. For each of the 4 years over the period 1995–1998, the 
total sum of positive and negative life events was calculated.   
 
Urbanicity Consistent with previous work,39 urbanicity was defined as living in the urban 
region of the German city of Munich vs the surrounding areas of Munich. The urban area, 
thus defined, had a population density of 4061 persons per square mile; for the rural area, this 
was 553 persons per square mile.   
 
Familial History of Help Seeking The item P8 of the T0 M-CIDI, rating the proband’s report 
on whether any of the proband’s family members had ever sought help for emotional or 
mental problems, was used as a proxy for familial liability for mental disorder.   
 
Analyses   
 
All analyses were carried out with STATA 11.0. Using the MLOGIT command, multinomial 
logistic regression was used to predict the 3-level outcome variable of disorders of 
anxiety/depression with/without psychotic symptoms. Given the fact that this outcome was 
measured twice (lifetime at T2 and interval T2–T3 at T3), data were analyzed in the „long 
format“, each individual contributing 2 observations (T2 and T3) for analysis, conform 
previous work.35,36 In order to correct for the clustering of multiple observations within 
subjects, cluster- robust standard errors were computed using the CLUSTER option in the 
MLOGIT module in STATA. Individuals without disorders of anxiety/depression and without 
psychotic symptoms were the reference group. Presence of disorders of anxiety/depression 
with and without psychotic symptoms was predicted by (1) demographic variables (age, 
gender, and education), (2) course and severity variables (course of disorders of 
anxiety/depression, persistence of both schizotypy expression, negative symptoms, and 
suicidal thoughts), (3) variables relevant for onset of professional help (help-seeking behavior 
and caseness), and (4) risk factors (family history of mental disorder, trauma, life events, 
substance use, and urbanicity). All analyses were a priori adjusted for age, sex, and education. 
OR for disorders of anxiety/depression with and without psychotic symptoms were compared 
by Wald test using the postestimation TEST command in STATA.   
 
Risk Set. The risk set for analysis were individuals at T2 and T3 who (1) had no diagnosis of 
bipolar disorder or psychotic disorder, (2) had a diagnosis of disorders of anxiety/depression 
as defined above, and (3) did not present with psychotic symptoms in the absence of disorders 
of anxiety/depression as defined above. The reference group consisted of individuals who had 
neither psychotic/bipolar disorder nor anxiety/depression. This yielded a total risk set of 2118 
individuals at T2 and 2027 individuals at T3.   
 
Sensitivity Analysis. A planned sensitivity analysis was carried out excluding individuals with 
lifetime comorbid anxiety disorder and depressive disorder, sensitively using measures at T0, 
T2, and T3, in order to examine to what degree any differences between individuals with 
disorders of anxiety/depression with and without psychotic symptoms was mediated by 
comorbidity of anxiety and depression, which is associated with greater indices of illness 
severity and poorer prognosis.40   
 
Results   
 
Descriptives   
 
Before exclusion of individuals with bipolar disorder and psychotic disorder, the number of 
eligible individuals at T0 was N = 3021, at T2 N = 2548 (84%), and at T3 N = 2210 (73%). 
Of all individuals with disorders of anxiety/ depression, as defined for the purpose of this 
study, 27% also reported psychotic symptoms at any time point (36% at T2 and 19% at T3), 
vs 14% in those without (OR 2.23, 95% CI 1.89–2.66, P < .001)   
 
Associations of Demographics, Severity, Risk Factors, and Onset of Professional Help With 
Disorders of Anxiety/Depression With/Without Psychotic Symptoms   
 
Analyses in the risk set as defined above (described in table 1) revealed that participants with 
a disorder of anxiety/ depression with psychotic symptoms, compared with those without 
psychotic symptoms, were more likely to be male and younger (table 2). Lower education 
differentiated between disorders of anxiety/depression with and without psychotic symptoms, 
the former group having lower educational attainment. Measures of severity (persistence of 
both schizotypal and negative psychotic symptoms, suicidal ideation over T0–T3) and course 
(number of times diagnosed with disorders of anxiety/depression over T0–T3) were 
associated with both affective conditions but more strongly with disorders of 
anxiety/depression with psychotic symptoms. The same was found for associations with 
variables relevant for onset of professional help and risk factors: these variables were 
significantly associated with presence of disorders of anxiety/depression with and without 
psychotic symptoms but more strongly with disorders of anxiety/depression with psychotic 
symptoms.   
 
The sensitivity analyses showed that results were largely robust to exclusion of comorbid 
anxiety and depression states from the analyses (see last column table 2). Generally, all 
patterns remained similar, ie, quantitative differences were found between disorders of 
anxiety/depression with and without psychotic symptoms, with the strongest associations 
found for individuals with additional psychotic symptoms. Three predictors no longer 
discriminated significantly between the 2 groups, namely, use of cannabis (P < .0622), help 
seeking (P < .208), and life events that had occurred in the second year after baseline 
assessment (P < .068). However, the results still showed a trend toward quantitative 
differences and still displayed the strongest associations for individuals with additional 
psychotic symptoms.   
 
 
 
Discussion   
 
Findings   
 
Psychotic symptoms were reported in 27% of individuals with a disorder of 
anxiety/depression in a large sample of adolescents and young adults from the general 
population. Individuals with a disorder of anxiety/depression were also more likely to report 
psychotic symptoms than individuals without such a disorder. Both anxiety/depression 
disorder groups, ie, with and without psychotic symptoms, differed from controls (indicating 
lack of qualitative differences), but anxiety/depression with psychotic symptoms showed 
larger effect sizes than anxiety/depression without psychotic symptoms (indicating 
quantitative differences). Thus, anxiety/depression disorders with and without psychotic 
symptoms were distinguished quantitatively by indicators of severity, course, onset, and 
environmental and familial risks. The findings could not be attributed to comorbidity of 
anxiety and depression per se because the sensitivity analyses showed that the pattern of 
results was largely robust to exclusion of this comorbidity.   
 
Disorders of Anxiety/Depression With Psychosis: A Prevalent and More Severe Disorder   
 
The present findings confirm earlier work that psychopathological dimensions of affective 
dysregulation and reality distortion often co-occur.3,5,14,17 Most research on this co-occurrence 
was published from the perspective of psychosis research, thus focusing on the additional 
presence of disorders of anxiety/depression in individuals endorsing psychotic phenomena. 
However, the present study joins a novel line of research that takes an alternative perspective. 
Although previous work has shown that psychotic symptoms are common in clinical samples 
presenting with disorders of anxiety/depression,7,8 the current study aimed to quantify (1) the 
prevalence and (2) the consequences of psychotic symptoms in individuals with disorders of 
anxiety/depression in an epidemiological general population sample.   
 
The findings indicate that the sizeable subgroup of individuals with disorders of 
anxiety/depression and psychotic symptoms has a more severe condition than those without 
psychotic symptoms. These findings are in agreement with studies showing that comorbidity 
of affective and psychotic psychopathology is more severe and of poorer prognosis than 
disorders without multidimensional admixture.41 It also validates the interpretation of 
psychotic symptoms as complicating factors in disorders of anxiety/depression, characterizing 
a group of individuals with more severe pathology, earlier need for care, and more etiological 
loading.   
 
The results support a hypothesized continuum of vulnerability between affective 
dysregulation and reality distortion, in which individuals who are vulnerable for either 
dimension are also more prone to develop the other.7,12,43 Our results support this notion by 
showing that individuals with disorders of anxiety/depression are more prone to develop 
psychotic symptoms. 
 
Disorders of Anxiety/Depression, Psychotic Symptoms, and UHR Status   
 
Another explanation relevant to these findings is that individuals with disorders of 
anxiety/depression and psychotic symptoms are in a prodromal stage of psychotic disorder. 
The rationale for this reasoning is that affective symptoms (1) form an intrinsic dimension of 
psychosis,29 (2) are the most common (and earliest) retrospectively reported prodromal 
symptoms6 that may come online earlier than psychotic phenomena that form the core 
characteristic of UHR status in help-seeking individuals, and (3) predict transition and worse 
outcome in UHR samples.11,44 This interpretation, however, is not likely, given (1) the very 
large number of individuals in the present study reporting both disorders of 
anxiety/depression and psychotic symptoms, (2) the low prevalence of psychotic disorder in 
the population, and (3) the low number of individuals within the group at ultra-high risk for 
psychosis that actually make the transition to psychotic disorder.44 Conversely, however, it 
can be considered likely that many of the help-seeking individuals presenting as UHR for 
psychosis actually represent the group with disorders of anxiety/depression with comorbid 
psychotic symptoms. In other words, a substantial proportion of help-seeking individuals 
presenting as UHR may in fact present with disorders of anxiety/depression complicated by 
psychotic symptoms, which is supported by (1) the observation that the great majority of 
UHR individuals initially carries a diagnosis of anxiety disorder and/or depression9–11 and (2) 
reports that part of this group responds favorable to antidepressant medication.45 Because 
disorders of anxiety/depression have traditionally been considered as „nonpsychotic“, this 
explanation has not been considered before.   
 
Diagnostic Implications   
 
Mental disorder nosology is based on the theory that the signs and symptoms associated with 
mental ill health fluctuate as a function of an underlying latent diagnostic construct. However, 
disorders in practice do not occur in isolation, be it a combination of affective and psychotic 
disorder3 or mental disorder diagnoses in general.46 The data, in combination with previous 
work, suggest that psychopathology may be considered as a network of symptom dimensions 
that reciprocally impact each other over time and are linked as part of a homeostatic 
mechanism, time, and/or share liability. An approach that possibly can accommodate this type 
of variation over time is the clinical staging model,47 in combination with a network model of 
psychopathology.48 Thus, reciprocally impacting symptoms sharing degrees of liability may 
develop across stages of severity and comorbidity.   
 
Methodological Issues   
 
The current results should be interpreted in light of the strengths and limitations of the study. 
A major strength of the study was that it addressed the copresence of disorders of 
anxiety/depression and psychotic symptoms, assessed by psychologists who were allowed to 
probe with clinical questioning, in a large, representative population study that was followed 
over an extended period. However, the relatively long follow-up period with only 3 
assessments also limits the possibilities of constructing dynamic, microlevel models of the 
development of reciprocally impacting domains of psychopathology. Second, even though 
psychotic symptoms were assessed by psychologists using clinical questioning, false-positive 
ratings are likely to have occurred. However, the effect of this would be conservative rather 
than to give rise to spurious associations. Furthermore, even „false-positive“ ratings of 
positive psychotic symptoms have been shown to be predictive of later (psychotic and 
affective) pathology25 and therefore are important predictors to include. Third, some of the 
risk factors that were investigated should be interpreted carefully. For example, the variable 
reflecting caseness was assigned by the same interviewer enquiring about psychopathology 
and therefore may be biased. Finally, some of the assessments of the exposure variables may 
have been biased because individuals who are more severely ill may report greater degree of 
exposure to, eg, childhood trauma or life events.   
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